From Reuters.

AstraZeneca shares fell 1.9% after a US FDA panel voted against recommending its experimental breast cancer drug, citing study design concerns.

#News #Reuters #Newsfeed #astrazeneca #health #breastcancer #usa #unitedstates #fda #business #businessnews

Read the story here: https://reut.rs/3OCHwrX

👉 Subscribe: https://reut.rs/4b8fRGn

Keep up with the latest news from around the world: https://www.reuters.com/
Follow Reuters on Facebook: https://www.facebook.com/Reuters
Follow Reuters on X: https://twitter.com/Reuters
Follow Reuters on Instagram: https://www.instagram.com/reuters/?hl=en